KROS
Price
$17.30
Change
-$0.17 (-0.97%)
Updated
Nov 13 closing price
Capitalization
527.52M
110 days until earnings call
Intraday BUY SELL Signals
SPRY
Price
$8.41
Change
-$0.53 (-5.93%)
Updated
Nov 13 closing price
Capitalization
831.32M
125 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KROS vs SPRY

Header iconKROS vs SPRY Comparison
Open Charts KROS vs SPRYBanner chart's image
Keros Therapeutics
Price$17.30
Change-$0.17 (-0.97%)
Volume$1.07M
Capitalization527.52M
ARS Pharmaceuticals
Price$8.41
Change-$0.53 (-5.93%)
Volume$2.5M
Capitalization831.32M
KROS vs SPRY Comparison Chart in %
View a ticker or compare two or three
VS
KROS vs. SPRY commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Buy and SPRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (KROS: $17.47 vs. SPRY: $8.94)
Brand notoriety: KROS and SPRY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 225% vs. SPRY: 98%
Market capitalization -- KROS: $527.52M vs. SPRY: $831.32M
KROS [@Biotechnology] is valued at $527.52M. SPRY’s [@Biotechnology] market capitalization is $831.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green whileSPRY’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • SPRY’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than SPRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish while SPRY’s TA Score has 4 bullish TA indicator(s).

  • KROS’s TA Score: 5 bullish, 4 bearish.
  • SPRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KROS is a better buy in the short-term than SPRY.

Price Growth

KROS (@Biotechnology) experienced а +11.63% price change this week, while SPRY (@Biotechnology) price change was -1.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

KROS is expected to report earnings on Mar 04, 2026.

SPRY is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPRY($831M) has a higher market cap than KROS($528M). SPRY has higher P/E ratio than KROS: SPRY (151.25) vs KROS (11.10). KROS YTD gains are higher at: 10.360 vs. SPRY (-15.213). KROS has higher annual earnings (EBITDA): 25.5M vs. SPRY (-59.34M). KROS has more cash in the bank: 690M vs. SPRY (240M). SPRY has less debt than KROS: SPRY (1.66M) vs KROS (18M). KROS has higher revenues than SPRY: KROS (233M) vs SPRY (112M).
KROSSPRYKROS / SPRY
Capitalization528M831M64%
EBITDA25.5M-59.34M-43%
Gain YTD10.360-15.213-68%
P/E Ratio11.10151.257%
Revenue233M112M208%
Total Cash690M240M288%
Total Debt18M1.66M1,084%
TECHNICAL ANALYSIS
Technical Analysis
KROSSPRY
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 29 days ago
79%
Bearish Trend 21 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 7 days ago
74%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
KROS
Daily Signal:
Gain/Loss:
SPRY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMYCX46.700.11
+0.24%
Putnam Core Equity Fund C
SMBYX41.870.09
+0.22%
ClearBridge Mid Cap I
WCMJX10.820.01
+0.09%
WCM SMID Quality Val Fd Investor
CTASX45.190.01
+0.02%
Calamos Timpani Small Cap Growth A
GSIOX31.54-0.04
-0.13%
Goldman Sachs Small Cap Gr Insghts Instl

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+3.37%
INO - KROS
53%
Loosely correlated
-2.00%
AXON - KROS
43%
Loosely correlated
-0.47%
RAPT - KROS
39%
Loosely correlated
-0.27%
DNLI - KROS
39%
Loosely correlated
-0.34%
ALT - KROS
39%
Loosely correlated
-1.17%
More

SPRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with LPCN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
+2.00%
LPCN - SPRY
63%
Loosely correlated
+1.04%
KROS - SPRY
34%
Loosely correlated
+3.37%
ANAB - SPRY
33%
Poorly correlated
-1.40%
DAWN - SPRY
31%
Poorly correlated
-0.19%
REPL - SPRY
31%
Poorly correlated
-0.99%
More